Qalsody (Tofersen) Becomes First-of-Its-Kind Treatment for ALS
XTalks
MAY 1, 2023
Tofersen was discovered by Ionis Pharmaceuticals, and Biogen licensed tofersen from Ionis under a collaborative development and license agreement. Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins.
Let's personalize your content